The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Patients with pancreatic ductal adenocarcinoma (PDAC) usually have a dismal prognosis, and even after curative resection most patients will have disease relapse and ultimately die. Nonetheless, adjuvant chemotherapy has considerably improved the outcomes of patients who are able to undergo surgery. The PREOPANC trial provides some evidence supporti...
Alternative Titles
Full title
The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2654983012
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2654983012
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/s41571-022-00612-6
